Abbott Laboratories Change in Accounts Receivable 2010-2025 | ABT
Abbott Laboratories annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
- Abbott Laboratories change in accounts receivable for the quarter ending June 30, 2025 was $-0.672B, a 41.18% increase year-over-year.
- Abbott Laboratories change in accounts receivable for the twelve months ending June 30, 2025 was $-2.158B, a 53.38% increase year-over-year.
- Abbott Laboratories annual change in accounts receivable for 2024 was $-0.691B, a 94.1% increase from 2023.
- Abbott Laboratories annual change in accounts receivable for 2023 was $-0.356B, a 423.53% increase from 2022.
- Abbott Laboratories annual change in accounts receivable for 2022 was $-0.068B, a 82.25% decline from 2021.
| Abbott Laboratories Annual Change in Accounts Receivable (Millions of US $) |
|
|---|---|
| 2024 | $-691 |
| 2023 | $-356 |
| 2022 | $-68 |
| 2021 | $-383 |
| 2020 | $-924 |
| 2019 | $-275 |
| 2018 | $-190 |
| 2017 | $-207 |
| 2016 | $-177 |
| 2015 | $-171 |
| 2014 | $-195 |
| 2013 | $-113 |
| 2012 | $36 |
| 2011 | $-670 |
| 2010 | $-395 |
| 2009 | $-388 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $229.305B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Boston Scientific (BSX) | United States | $152.872B | 36.46 |
| Stryker (SYK) | United States | $146.007B | 29.72 |
| EssilorLuxottica (ESLOY) | France | $145.127B | 0.00 |
| Medtronic (MDT) | Ireland | $119.233B | 16.91 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.282B | 0.00 |
| Haleon (HLN) | United Kingdom | $43.313B | 24.74 |
| ResMed (RMD) | United States | $41.712B | 29.83 |
| Agilent Technologies (A) | United States | $33.861B | 22.07 |
| GE HealthCare Technologies (GEHC) | United States | $33.512B | 15.75 |
| Terumo (TRUMY) | Japan | $27.642B | 32.75 |
| Koninklijke Philips (PHG) | Netherlands | $26.451B | 17.50 |
| Insulet (PODD) | United States | $22.615B | 75.77 |
| Zimmer Biomet Holdings (ZBH) | United States | $20.354B | 12.96 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $15.855B | 0.00 |
| Baxter (BAX) | United States | $12.419B | 9.60 |
| Sunny Optical Technology (SNPTF) | China | $10.800B | 0.00 |
| Demant (WILYY) | Denmark | $8.121B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.731B | 28.40 |
| Lantheus Holdings (LNTH) | United States | $3.684B | 9.96 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.430B | 24.00 |
| Prestige Consumer Healthcare (PBH) | United States | $3.198B | 14.19 |
| Perrigo (PRGO) | Ireland | $3.123B | 7.80 |
| ICU Medical (ICUI) | United States | $2.986B | 20.33 |
| Haemonetics (HAE) | United States | $2.589B | 11.56 |
| LeMaitre Vascular (LMAT) | United States | $2.171B | 46.56 |
| Curaleaf Holdings (CURLF) | Canada | $1.782B | 0.00 |
| AtriCure (ATRC) | United States | $1.762B | 0.00 |
| QuidelOrtho (QDEL) | United States | $1.761B | 11.08 |
| Green Thumb Industries (GTBIF) | United States | $1.601B | 68.73 |
| AdaptHealth (AHCO) | United States | $1.283B | 18.24 |
| Phibro Animal Health (PAHC) | United States | $1.243B | 15.89 |
| Acuren (TIC) | United States | $1.190B | 0.00 |
| Neogen (NEOG) | United States | $1.179B | 18.72 |
| BioLife Solutions (BLFS) | United States | $1.166B | 2434.00 |
| Tilray Brands (TLRY) | Canada | $1.134B | 0.00 |
| Valneva SE (VALN) | France | $0.981B | 0.00 |
| InMode (INMD) | Israel | $0.907B | 8.39 |
| Kestra Medical Technologies (KMTS) | United States | $0.824B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.665B | 0.00 |
| Surmodics (SRDX) | United States | $0.536B | 0.00 |
| ZimVie (ZIMV) | United States | $0.532B | 20.49 |
| SNDL (SNDL) | Canada | $0.531B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.482B | 0.00 |
| CeriBell (CBLL) | United States | $0.451B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.451B | 15.53 |
| Owens & Minor (OMI) | United States | $0.439B | 3.89 |
| Verano Holdings (VRNOF) | United States | $0.438B | 0.00 |
| Evolus (EOLS) | United States | $0.435B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.364B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.331B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.330B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.312B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.287B | 0.00 |
| Omeros (OMER) | United States | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.267B | 20.26 |
| Sanara MedTech (SMTI) | United States | $0.264B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.254B | 0.00 |
| Brainsway (BWAY) | Israel | $0.245B | 49.92 |
| Cerus (CERS) | United States | $0.238B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.234B | 0.00 |
| High Tide (HITI) | Canada | $0.216B | 0.00 |
| Quanterix (QTRX) | United States | $0.212B | 0.00 |
| Exagen (XGN) | United States | $0.209B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.202B | 0.00 |
| Organigram Global (OGI) | Canada | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.83 |
| TriSalus Life Sciences (TLSI) | United States | $0.172B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.156B | 0.00 |
| Biote (BTMD) | United States | $0.144B | 4.79 |
| Jushi Holdings (JUSHF) | United States | $0.116B | 0.00 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.094B | 12.08 |
| Quipt Home Medical (QIPT) | United States | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.085B | 0.00 |
| Apyx Medical (APYX) | United States | $0.082B | 0.00 |
| Safety Shot (SHOT) | United States | $0.078B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.073B | 0.00 |
| Agape ATP (ATPC) | $0.063B | 0.00 | |
| ImmuCell (ICCC) | United States | $0.055B | 32.12 |
| Veru (VERU) | United States | $0.053B | 0.00 |
| Zynex (ZYXI) | United States | $0.046B | 0.00 |
| Nephros (NEPH) | United States | $0.045B | 35.42 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.036B | 14.05 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.029B | 0.00 |
| Senestech (SNES) | United States | $0.024B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.018B | 0.00 |
| INLIF (INLF) | $0.017B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.014B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.008B | 0.00 |
| Sharps Technology (STSS) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InterCure (INCR) | Israel | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |